Read human trial summaries with the population, comparator, studied exposure, timeframe and source scope visible.
Selected from the completed-summary collection, not a systematic review or exhaustive literature search. Human reports appear first; reviews and preclinical work retain their labels.
Search, filter and compare →A randomized, blinded trial compared retatrutide with placebo for weight loss over 48 weeks.
Digestive side effects were common and dose-related. Heart rate also increased with dose. These findings describe this trial's population and follow-up.
Randomized, double-blind phase 3 trial compared weekly retatrutide with placebo for 40 weeks. The primary outcome was HbA1c, a blood-sugar marker; weight change was secondary.
No author-stated limitations were available in the abstract. The comparison covered 40 weeks against placebo, not an active drug.
A randomized, double-blind phase 2 substudy in adults with type 2 diabetes compared retatrutide with placebo and dulaglutide. Its primary outcome was total fat-mass change measured by body-composition scans over 36 weeks.
No author-stated limitations were available in the abstract. Only 103 of 189 participants completed treatment and paired scans.
A randomized, double-blind, placebo-controlled phase two substudy tested once-weekly retatrutide for reducing liver fat.
This was a substudy of ninety-eight selected participants rather than a standalone broad liver-disease trial.
The trial compared several weekly retatrutide regimens with placebo and dulaglutide for glucose control and body weight over 24 to 36 weeks.
Only 79% of participants completed study treatment. Methodological quality was not formally appraised here.
A 12-week randomized, double-blind phase 1b trial in adults with type 2 diabetes compared ascending retatrutide doses with placebo and dulaglutide. Safety and tolerability were primary outcomes; glucose, weight and drug-processing measures were secondary.
No author-stated limitations were available in the abstract. Of 72 treated participants, 29 discontinued prematurely.
Discovery research assessed LY3437943, later known as retatrutide, a peptide activating glucagon, GIP and GLP-1 receptors, through laboratory experiments, obese-mouse studies and an early phase 1 single-dose study.
Authors called for further clinical assessment. The mouse mechanism does not establish the same mechanism or effectiveness in humans; the abstract provides no detailed adverse-event counts.
A kidney-safety analysis reported kidney impairment, dehydration and low blood pressure. One retatrutide participant had serious acute kidney injury, possibly secondary to COVID-19.
The analysis was exploratory, without adjustment for multiple comparisons. Few participants had existing kidney disease, follow-up was short, and no kidney outcome events occurred; prevention of kidney failure was not established.
A review of cardiovascular research on single, dual and triple incretin-receptor agonists, including effects beyond blood-sugar control.
For triple agonists, phase 2 findings concerned surrogate measures; phase 3 cardiovascular outcome results were still awaited.
Abstract-based narrative review of incretin weight-loss drugs and whether resistance exercise could help preserve lean mass; it did not test a new intervention or comparator.
No direct trial of resistance exercise during incretin therapy is presented; the exercise recommendation is the authors’ proposal, so preservation during treatment remains untested here.
Review of current and pipeline obesity medicines, emphasizing GLP-1 and combinations with GIP, glucagon, or amylin. It does not report one intervention, comparator, or follow-up period.
The abstract gives no review-selection methods, study counts, or formal quality assessment. Its statement that early pipeline data may exceed tirzepatide is not a head-to-head finding, so methodological quality remains unassessed.